Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 02, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of shareholding changes within a specific employee retirement plan and does not contain financial performance data.
Material Changes
The filing details changes in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- December 21, 2006: Holdings decreased from 17,326,404 to 17,313,005 ADRs at an average price of $52.42.
- December 28, 2006: Holdings decreased from 17,313,005 to 17,271,622 ADRs at an average price of $52.14.
These movements were driven by fund activity rather than direct trading by the directors.
Management Commentary and Risks
The Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two directors, Dr. J P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees. The filing states there are no unusual items or specific risks beyond the standard disclosure requirements under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Confirm the total reduction in ADR holdings for the Plan between December 21 and December 28, 2006.
- Verify the average transaction prices of $52.42 and $52.14 against market data for the respective dates.
- Note that the disclosed transactions reflect fund movements rather than direct personal trading by the named directors.